Acadian Asset Management
PBYI icon

Acadian Asset Management’s Puma Biotechnology PBYI Stock Holding History

Acadian Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
2,053,523
+11,764
+0.6% +$86.1K 0.02% 462
2026
Q1 		$13M Buy
2,041,759
+16,936
+0.8% +$109K 0.02% 458
2025
Q4 		$12M Sell
2,024,823
-28,482
-1% -$151K 0.02% 443
2025
Q3 		$10.9M Buy
2,053,305
+45,159
+2% +$192K 0.02% 461
2025
Q2 		$6.88M Hold
2,008,146
– – 0.01% 506
2025
Q1 		$5.94M Buy
2,008,146
+36,018
+2% +$113K 0.02% 455
2024
Q4 		$6.01M Buy
1,972,128
+3,129
+0.2% +$9.1K 0.02% 468
2024
Q3 		$5.02M Buy
1,968,999
+17,791
+0.9% +$53.9K 0.02% 500
2024
Q2 		$6.36M Sell
1,951,208
-5,305
-0.3% -$23.3K 0.02% 443
2024
Q1 		$10.4M Buy
1,956,513
+39,239
+2% +$211K 0.04% 291
2023
Q4 		$8.3M Buy
1,917,274
+59,274
+3% +$196K 0.03% 330
2023
Q3 		$4.88M Sell
1,858,000
-16,123
-0.9% -$54.9K 0.02% 443
2023
Q2 		$6.61M Sell
1,874,123
-736
-0% -$2.3K 0.03% 385
2023
Q1 		$5.79M Buy
1,874,859
+61,819
+3% +$233K 0.03% 420
2022
Q4 		$7.67M Sell
1,813,040
-25,902
-1% -$89.4K 0.04% 332
2022
Q3 		$4.35M Buy
1,838,942
+30,114
+2% +$87.9K 0.02% 437
2022
Q2 		$5.15M Buy
1,808,828
+116,929
+7% +$291K 0.03% 407
2022
Q1 		$4.87M Sell
1,691,899
-54,382
-3% -$141K 0.02% 472
2021
Q4 		$5.3M Buy
1,746,281
+446,734
+34% +$1.94M 0.02% 442
2021
Q3 		$9.11M Buy
1,299,547
+72,068
+6% +$540K 0.03% 331
2021
Q2 		$11.3M Buy
1,227,479
+12,002
+1% +$122K 0.04% 305
2021
Q1 		$11.8M Buy
1,215,477
+91,945
+8% +$1.03M 0.05% 304
2020
Q4 		$11.5M Sell
1,123,532
-223,085
-17% -$2.26M 0.04% 311
2020
Q3 		$13.6M Buy
1,346,617
+79,686
+6% +$811K 0.06% 264
2020
Q2 		$13.2M Buy
1,266,931
+391,666
+45% +$4.05M 0.06% 280
2020
Q1 		$7.39M Buy
875,265
+36,143
+4% +$351K 0.04% 312
2019
Q4 		$7.34M Buy
839,122
+456,921
+120% +$3.78M 0.03% 367
2019
Q3 		$4.11M Buy
382,201
+127,487
+50% +$1.38M 0.02% 505
2019
Q2 		$3.24M Buy
254,714
+250,130
+5,457% +$5.76M 0.02% 482
2019
Q1 		$178K Buy
+4,584
New +$140K ﹤0.01% 1383

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return

Acadian Asset Management's PBYI Position: Q2 2026 in Review

Acadian Asset Management increased its Puma Biotechnology (PBYI) stake by 0.58% in Q2 2026, buying an estimated $86.1K and bringing the position to 2,053,523 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #462.

Acadian Asset Management first reported a position in PBYI in Q1 2019 and has held it in 30 quarters since. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Acadian Asset Management held 2,053,523 shares of Puma Biotechnology worth $16.6M as of Q2 2026.
  • Acadian Asset Management bought 11,764 Puma Biotechnology shares in Q2 2026, an estimated $86.1K.
  • Puma Biotechnology made up 0.02% of Acadian Asset Management's portfolio in Q2 2026, its #462 holding.
  • Acadian Asset Management first reported a position in Puma Biotechnology in Q1 2019 and has held it in 30 quarters since.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.